Newsstand | Page 29 | Aplastic Anemia & MDS International Foundation

Newsstand

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Specialized technique effective in identifying chromosomal abnormalities, improving prognosis for MDS

Originally Published: 07/31/2012
Note: This abstract was presented at the 2012 ASCO annual meeting in June 2012. The full abstract may be reviewed on the ASCO Annual Meeting Web site. Use the abstract number to access the full report. Abstract # 6521 To date, the most widely used prognostic classification system for myelodysplastic syndrome (MDS) is the International Prognostic Scoring System (IPSS). The first IPSS was derived from a study published in 1997. The IPSS separates patients into four distinct subgroups based solely on the percentage of bone marrow blasts, cytogenetics (branch of genetics which studies the...

Sapacitibine shows promise for high-risk MDS patients

Originally Published: 07/30/2012
Note: This abstract was presented at the 2012 ASCO annual meeting in June 2012. The full abstract may be reviewed on the ASCO Annual Meeting Web site. Use the abstract number to access the full report. Abstract # 6520 Myelodysplastic syndrome (MDS) is a heterogeneous disease, with varied options for treatment. These range from supportive care, which includes blood product transfusions and the use of growth factors, to intensive therapy with allogeneic hematopoietic stem cell transplantation (HSCT). Treatment selection should be based on the patient’s age, performance status, and...

European Study of Horse ATG vs. Rabbit ATG for Treatment of Aplastic Anemia

Originally Published: 07/03/2012
Aplastic anemia is a blood disease caused by the destruction of a person’s normal bone marrow cells by specific white blood cells known as T-lymphocytes. One of the treatment options is to give the patient medications that suppress the immune system, specifically the T-lymphocytes. The best immunosuppressive therapy for patients with severe aplastic anemia (sAA) is a combination of anti-thymocyte globulin (ATG) and cyclosporine (CsA). Combining these two drugs results in response rates of 60-75%. Two types of ATG are currently available.  One derived from the horse, known as horse ATG (hATG...

Overview of stem cell transplantation for aplastic anemia

Originally Published: 07/03/2012
Patients with newly diagnosed severe aplastic anemia (sAA) are treated with drugs that suppress the immune system, antithymocyte globulin (ATG) plus cyclosporine (CsA), or an allogeneic hematopoietic stem cell transplantation (Allo-HSCT).  An Allo-HSCT is a type of bone marrow transplant that uses stem cells taken from another person, known as the donor source or source of the graft. The donor can be the patient’s brother or sister.  This is called a “matched sibling or related donor”.  If a patient does not have a matched sibling or related donor, an unrelated individual that shares...

Allogenic stem cell transplantation for older patients with AML and MDS

Originally Published: 06/29/2012
Note: This abstract was presented at the 2012 ASCO annual meeting in June 2012. The full abstract may be reviewed on the ASCO Annual Meeting Web site. Use the abstract number to access the full report. Abstract # 6529 Myelodysplastic syndrome (MDS) is often a disease of advanced age with a majority of patients over the age of 65 years at the time of their diagnosis. Although some patients with MDS enjoy a long period of time with minimal symptoms or change in their disease, some patients experience a rapid progression to either bone marrow failure or acute myeloid leukemia (AML). For...

Effectiveness of lenalidomide in patients over 75 vs. patients under 75 with RBC transfusion-dependent low/int-1-risk MDS and del5q

Originally Published: 06/29/2012
Note: This abstract was presented at the 2012 ASCO annual meeting in June 2012. The full abstract may be reviewed on the ASCO Annual Meeting Web site. Use the abstract number to access the full report. Abstract # 6522 The FDA approved lenalidomide in 2005 for treatment of lower risk MDS patients (low or intermediate-1 risk IPSS score) with deletion 5q abnormalities who are dependent on red blood cell (RBC) transfusions.  This approval was based on the results of the MDS-003 study, which showed that a majority of such patients who were treated with lenalidomide achieved sustained...

Factors affecting response to treatment for secondary MDS and AML

Originally Published: 06/29/2012
Note: This abstract was presented at the 2012 ASCO annual meeting in June 2012. The full abstract may be reviewed on the ASCO Annual Meeting Web site. Use the abstract number to access the full report. Abstract # 6603 Secondary or t-MDS It is important to recognize that, while secondary MDS (t-MDS) represents approximately 10% of MDS cases, the chance of developing MDS if you are treated for another cancer is very low - less than 1/2 of 1% (0.5%) in most cases, though the risk increases in patients who receive multiple rounds of chemotherapy and radiation therapy, and also in those who...

Risk of developing MDS and AML after radiation treatment for breast cancer

Originally Published: 06/29/2012
Note: This abstract was presented at the 2012 ASCO annual meeting in June 2012. The full abstract may be reviewed on the ASCO Annual Meeting Web site. Use the abstract number to access the full report. Abstract # 6560 Secondary or t-MDS It is important to recognize that, while secondary MDS (t-MDS) represents approximately 10% of MDS cases, the chance of developing MDS if you are treated for another cancer is very low - less than 1/2 of 1% (0.5%) in most cases, though the risk increases in patients who receive multiple rounds of chemotherapy and radiation therapy, and also in those who...

New MDS Prognostic Scoring System May Lead to More Effective Treatment

Originally Published: 05/30/2012
The International Prognostic Scoring System (IPSS) is used by doctors to evaluate the seriousness of MDS in each patient.  It has prognostic value (i.e., predictive with respect to disease outcome) and will help to develop a treatment plan. One of the components of this scoring system is a genetic analysis.  This by itself allows 86% of all MDS patients to be classified in one of 3 groups (with either poor, intermediate or good prognosis).  However, 14% of MDS patients carry genetic abnormalities that cannot be classified with the current IPSS. In this study, 2,902 patients with either MDS...

Stem Cell Transplants May Be An Option for Some Elderly MDS Patients

Originally Published: 05/30/2012
Myelodysplastic Syndromes (MDS) is considered a disease of the hematopoietic (blood-forming) stem cells (HSCs) that are housed in the bone marrow.  Replacing diseased HSCs with healthy HSCs from healthy donors (through a procedure called allogeneic (i.e., not genetically related) bone marrow transplantation (aBMT)) is the only cure for MDS. In order to kill the diseased cells and to make space in the bone marrow so that transplanted healthy HSCs can be received, patients are “conditioned” prior to the actual transplant. This so-called “conditioning regimen” is unfortunately associated with a...